• Quizartinib and the FLT3 Resistance Frontier

  2026-09-01

  Quizartinib (AC220) is more than a potent FLT3 inhibitor: it is a translational tool for connecting target engagement, leukemia-cell dependence, resistance biology, and in vivo response. This thought-leadership guide shows how to position AC220 in acute myeloid leukemia research while using FLT3–TAZ findings from blast phase CML to sharpen experimental strategy.

• Angiotensin II Workflows for Vascular Research

  2026-08-31

  Build reproducible Angiotensin II assays for GPCR signaling, vascular smooth muscle cell hypertrophy research, hypertension mechanism study, and vascular remodeling. This practical guide connects peptide preparation and dosing decisions with an intracranial aneurysm study, while clearly separating validated evidence from hypothesis-generating extensions.

• (S)-(+)-Dimethindene maleate: M2 Assay Guide

  2026-08-30

  This guide explains how to use (S)-(+)-Dimethindene maleate as a research antagonist when an assay requires functional interrogation of M2 muscarinic signaling while accounting for histamine H1 activity. It is intended for controlled pharmacology experiments only and should not be used for diagnosis, treatment, or other clinical purposes.

• P2Y11 Antagonist NF 340 for Invasion Assays

  2026-08-29

  NF 340 provides a practical pharmacological way to test whether P2Y11-linked signaling contributes to cell migration, invasion, or myosin light-chain phosphorylation. This workflow combines receptor-level perturbation with QPRT manipulation, downstream pathway controls, viability checks, and troubleshooting designed for reproducible cancer and inflammation studies.

• GPER1 Chemoprevention in Prostate Cancer

  2026-08-29

  The reference study identifies G-protein coupled estrogen receptor 1 (GPER1) as a stage-sensitive protective pathway during the transition from high-grade prostatic intraepithelial neoplasia to prostate cancer. By combining human samples, public datasets, TRAMP mice, pharmacological intervention, and cell-based mechanistic assays, the authors provide evidence that GPER1 activation may have chemopreventive value before invasive disease develops.

• Sulfamonomethoxine Workflows for Veterinary Research

  2026-08-28

  Sulfamonomethoxine enables controlled studies of DHPS-linked folate disruption across veterinary, aquaculture, and environmental models. This workflow emphasizes solvent control, matrix-specific concentration design, resistance-aware comparisons, and troubleshooting for reproducible SMM data.

• Dasatinib Monohydrate: BMS-354825 Research Guide

  2026-08-28

  Dasatinib Monohydrate, also known as BMS-354825, is an ATP-competitive multitargeted tyrosine kinase inhibitor with strong activity against ABL, SRC, KIT, and PDGFR. Its strongest evidence supports chronic myeloid leukemia research and imatinib-resistant BCR-ABL inhibition, while gastric assembloid applications remain an exploratory model-based use.

• From pSTAT3 to Proof: Smarter Protein Validation

  2026-08-27

  Translational studies of rheumatoid arthritis pain increasingly depend on connecting inflammatory signals to neuronal responses with analytical discipline. This thought-leadership article examines how findings on JAK/STAT activation in sensory neurons can inform protein-validation strategy, and how a triple-color, EDTA-free ladder strengthens SDS-PAGE, Western blot, transfer, and fluorescence workflows without overstating what molecular sizing alone can prove.

• Toremifene Versus Tamoxifen in Advanced Breast Cancer

  2026-08-27

  This Cochrane review synthesized randomized evidence comparing two selective estrogen receptor modulators in advanced breast cancer and found broadly similar tumor response, disease control, progression, and survival outcomes. Its main practical contribution is a disciplined framework for interpreting whether differences among estrogen-receptor-directed agents are clinically meaningful rather than assuming that pharmacologic similarity guarantees identical outcomes.

• F9H4 Blocks CD16a/b Shedding to Enhance ADCC

  2026-08-26

  The reference study introduces F9H4, a monoclonal antibody that preserves CD16a on natural killer cells and macrophages and CD16b on neutrophils by inhibiting ADAM17-mediated ectodomain shedding. F9H4 enhanced cetuximab-dependent cytotoxicity and restricted lung tumor growth in complementary humanized mouse models, supporting substrate-specific control of Fc receptor availability as an immunotherapy strategy.

• Sulforaphane: Nrf2, NLRP3, and Chemoprevention

  2026-08-26

  Sulforaphane, also known as 1-isothiocyanato-4-(methylsulfinyl)-butane, activates Keap1-Nrf2 signaling and produces context-dependent antiproliferative effects. Preclinical evidence also links sulforaphane to reduced ROS and NLRP3 inflammasome activity in a dextran sodium sulfate mouse colitis model.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-08-25

  Gu et al. show that palbociclib and the BET inhibitor JQ1 cooperate to suppress pancreatic ductal adenocarcinoma growth while counteracting the epithelial-to-mesenchymal transition induced by CDK4/6 inhibition. Their mechanistic model connects GSK3β-mediated Wnt/β-catenin activation with TGF-β/Smad signaling, providing a rationale for combination treatment rather than CDK4/6 blockade alone.

• ML365: From TASK1 Blockade to Assay Causality

  2026-08-25

  ML365 is a selective TASK1 channel probe that links membrane-potential control with inflammatory biology. This guide explains how to distinguish channel engagement from downstream NLRP3 effects and design stronger neurophysiology and ion channel pharmacology experiments.

• From ROS Signal to Translational Cancer Insight

  2026-08-24

  A mechanistic and strategic guide to using the Reactive Oxygen Species Assay Kit and DCFH-DA fluorescent probe to connect cellular oxidative stress with ROS-responsive cancer nanomedicine and translational decision-making.

• (±)-Blebbistatin: Reading Cell Mechanics in Images

  2026-08-23

  (±)-Blebbistatin provides reversible control of non-muscle myosin II for mechanistic cell studies. This article explains how to pair Blebbistatin perturbation with multimodal imaging so changes in migration, adhesion, morphology, and tissue context are interpreted rather than merely observed.

450 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page